Britain and America have secured a major trade agreement that will guarantee zero tariffs on British medicine products entering the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to boost funding on medicines through the NHS. This move guarantees that import taxes on these vital exports will remain at zero for a timeframe of the next three years.
This deal follows previous statements to hike import taxes on branded drug products, with figures discussed reaching double the cost.
"This agreement between the UK reinforces the international landscape for cutting-edge drugs and introduces much-needed equity to transatlantic pharmaceutical trade," a statement noted.
Economic Impact
Drugs represent one of the the United Kingdom's largest exports to the America, which is clearly the largest destination for large UK drugmakers.
Trade data show that in the year to the end of the third quarter, the UK sold drugs totaling billions to the US. This figure accounted for 17.4% of British export trade in that period.
"This deal protects work, increases investment and sets the stage for the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Specific UK Commitments
The pact involves several notable changes from the British government:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a goal to double overall public funding on drugs from 0.3% of the national economy to 0.6% over the next decade.
- Payback Limit: The percentage drug companies must pay back to the NHS to prevent overspending will be limited at 15%. Previously, repayments topped twenty percent.
Industry Background
This agreement comes amid a ongoing row between the sector and the British authorities over medicine costs and approval rates.
The disagreement were exacerbated by assertions that American customers were paying significantly more for the same drugs than people in the UK and Europe.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar expansions have been announced toward projects in the United States.
One official publicly accepted that the NHS had to spend more on medicines, noting that its expenditure on drugs had declined as a proportion of its resources over the past decade.
